Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TWEAK/FN14 inhibition synergizes with oncogene-directed tyrosine kinase inhibitors to overcome resistance across multiple driver contexts.

Scientific reports·2026
Same author

Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.

Cancers·2026
Same author

Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors.

Scientific reports·2026
Same author

Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods.

European radiology·2025
Same author

Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients.

Frontiers in immunology·2025
Same author

Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

Frontiers in oncology·2025

Related Experiment Video

Updated: Jun 11, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Thymic carcinoma: current and future therapeutic interventions.

Glen J Weiss1

  • 1Virginia G Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ 85238, USA. gweiss@tgen.org

Expert Opinion on Investigational Drugs
|July 16, 2010
PubMed
Summary

Thymic carcinoma, a rare cancer, requires precision medicine. Identifying key molecular drivers and vulnerabilities is crucial for effective treatment and improving patient outcomes.

Area of Science:

  • Oncology
  • Rare Cancers
  • Molecular Biology

Background:

  • Thymic carcinoma is an extremely rare malignancy with limited treatment options.
  • Despite 30 years of research, a cure remains elusive for most patients.

Purpose of the Study:

  • To review the current understanding of thymic carcinoma.
  • To discuss molecular characterization, staging, and treatment strategies.
  • To explore future directions for treating advanced thymic cancer.

Main Methods:

  • Literature review of thymic gland development and thymic carcinoma.
  • Analysis of molecular features, staging, and treatment guidelines.
  • Synthesis of current research on advanced disease management.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 11, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Main Results:

  • Thymic tumors exhibit heterogeneity, necessitating personalized treatment approaches.
  • Precision medicine is emerging as a key strategy to target specific tumor vulnerabilities.
  • Advances in molecular tools are enhancing our understanding of cancer subtypes.

Conclusions:

  • Targeting the molecular drivers of thymic carcinoma is essential for therapeutic success.
  • Identifying tumor vulnerabilities will maximize treatment impact for patients.
  • A shift from one-size-fits-all to precision medicine is critical for rare cancers.